Teva Pounces On US Revlimid Opportunity With Four Strength-Offering
Israeli Firm Has Partnered With Natco; December 2015 Settlement Provides For Entry
Teva has bolstered its oncology offering in the US by moving first on one of the largest small-molecule opportunities in the US: Bristol Myers Squibb’s multi-billion-dollar blockbuster Revlimid (lenalidomide) to treat multiple myeloma.
